Bladder Cancer Diagnostics Market Size, Share, Growth, Trends, and Global Industry Analysis: By Type of Condition (Transitional Cell Bladder Cancer, Invasive Bladder Cancer, Superficial Bladder Cancer, Squamous Cell Bladder Cancer, Other Rare Types), By Type of Test (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Bladder Ultrasound), By End User (Diagnostic Centers, Hospitals, Ambulatory Surgical Centers) and Region Forecast 2020-2031

Bladder Cancer Diagnostics Market size was valued at US$ 523.69 million in 2024 and is expected to reach US$ 746.76 million by 2031, growing at a significant CAGR of 5.2% from 2025-2031. Bladder cancer is a disease in which malignant cells are formed in the tissues of the bladder. Symptoms of bladder cancer include blood in the urine, pain with urination and low back pain. There are three types of bladder cancer that begin in the cells in the lining of the bladder. They are named as Transitional Cell Carcinoma, Squamous Cell Carcinoma, and Adenocarcinoma.

According to the National Institute of Health, approximately 45,000 men and 17,000 women per year are diagnosed with bladder cancer only in U.S. Globally the market for bladder cancer is increasing rapidly and is expected to grow rapidly from 2016 to 2022. According to The American Cancer Society's estimates for bladder cancer in the United States for 2017 are about 79,030 new cases of bladder cancer (about 60,490 in men and 18,540 in women) were diagnosed and about 16,870 deaths from bladder cancer (about 12,240 in men and 4,630 in women) are reporting. Bladder cancer accounts for about 5% of all new cancers in the US. It is the fourth most common cancer in men, but it is less common in women. In addition, the rise in awareness about bladder cancer and its available treatment options in the market, innovation in drug development, and subsequent technological advancements are expected to drive the market for bladder cancer diagnostics. Increasing number of mergers and acquisitions, the rise in a number of collaborations and partnerships, new product launches and growing awareness about the availability of bladder cancer diagnostics are some of the latest trends that have been observed in the market.

Key Developments:

• In May 2017. Roche Ltd. received USFDA approval for its VENTENA PD-L1 biomarket test pertaining to bladder cancer diagnosis. In 2016, Pacific Edge Limited launched officially its third bladder cancer diagnostic test Cxbladder Monitor in U.S.